These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38264861)

  • 41. Andexanet alfa for reversal of factor Xa inhibitors: a critical review of the evidence.
    Abdulrehman J; Eikelboom JW; Siegal DM
    Future Cardiol; 2019 Nov; 15(6):395-404. PubMed ID: 31668083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reversal of factor Xa inhibitors associated intracranial haemorrhage at a tertiary medical centre.
    Milioglou L; Liao K; Traeger J; McKenzie C; Burrelli C; Khunayfir AKB; Makii J; Hoffer A
    Blood Coagul Fibrinolysis; 2022 Jul; 33(5):261-265. PubMed ID: 35153278
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Factor-Xa Inhibitor-associated Bleeding with Andexanet Alfa or 4 Factor PCC: A Multicenter Feasibility Retrospective Study.
    Singer AJ; Concha M; Williams J; Brown CS; Fernandes R; Thode HC; Kirchman M; Rabinstein AA
    West J Emerg Med; 2023 Sep; 24(5):939-949. PubMed ID: 37788035
    [No Abstract]   [Full Text] [Related]  

  • 44. Andexanet alfa for the reversal of anticoagulant activity in patients treated with direct and indirect factor Xa inhibitors.
    Nafee T; Aslam A; Chi G; Pahlavani S; Nimri D; Kuchkuntla AR; Talib U; Michalak N; Daaboul Y; Korjian S; Gallo A; Gibson CM
    Expert Rev Cardiovasc Ther; 2017 Apr; 15(4):237-245. PubMed ID: 28282497
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
    Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
    J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Andexanet Alfa for Factor Xa Inhibitor Reversal in US Verified Trauma Centers: A National Survey.
    Fasanya C; Arrillaga A; Caronia C; Rothburd L; Japhe T; Hahn Y; Joseph P; Reci D; Eckardt P
    Clin Appl Thromb Hemost; 2024; 30():10760296241238013. PubMed ID: 38494906
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Deterioration free discharge comparison of andexanet-alfa and prothrombin complex concentrates (PCC) for reversal of factor Xa inhibitor associated bleeds.
    Keinath JJ; Lekura J; Hauser CD; Bajwa MK; Bloome ME; Kalus JS; Jones MC
    J Thromb Thrombolysis; 2023 Aug; 56(2):315-322. PubMed ID: 37289371
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Andexanet alfa: a recombinant mimetic of human factor Xa for the reversal of anticoagulant therapies.
    Escolar G; Diaz-Ricart M; Arellano-Rodrigo E
    Drugs Today (Barc); 2017 May; 53(5):271-282. PubMed ID: 28650000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Andexanet Alfa: What We Have Learned from Clinical Trials and Real-World Data.
    Frol S; Oblak JP; Šabovič M; Kermer P
    CNS Drugs; 2024 Mar; 38(3):163-168. PubMed ID: 38396232
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence-Based Minireview: Mortality and thrombosis in patients receiving prothrombin complex concentrates or andexanet alfa for the management of direct oral factor Xa inhibitor-associated major bleeding.
    Kimpton M; Siegal DM
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):204-208. PubMed ID: 31808849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Four-factor prothrombin complex concentrate versus andexanet alfa for the reversal of traumatic brain injuries.
    Sadek E; Curtiss W; Andrews J; Hecht J
    Emerg Med J; 2024 Feb; 41(3):162-167. PubMed ID: 38267194
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Andexanet alfa (ONDEXXYA
    Yajima T; Higashimori M; Takata C; Sasabe T
    Nihon Yakurigaku Zasshi; 2023; 158(1):89-100. PubMed ID: 36596498
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Andexanet alfa for the treatment of hemorrhage.
    Cervi A; Crowther M
    Expert Rev Hematol; 2018 Nov; 11(11):847-855. PubMed ID: 30296870
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and Safety of Andexanet Alfa Versus Four Factor Prothrombin Complex Concentrate for Emergent Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.
    Sarhan K; Mohamed RG; Elmahdi RR; Mohsen Y; Elsayed A; Zayed DM; Elkholi MA; Gabr N; El-Bialy EM; Serag I
    Neurocrit Care; 2024 Oct; ():. PubMed ID: 39379749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost comparison of andexanet versus prothrombin complex concentrates for direct factor Xa inhibitor reversal after hemorrhage.
    Frontera JA; Bhatt P; Lalchan R; Yaghi S; Ahuja T; Papadopoulos J; Joset D
    J Thromb Thrombolysis; 2020 Jan; 49(1):121-131. PubMed ID: 31664662
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Characterization of an andexanet alfa administration protocol guided by drug-specific quantitative anti-Xa assays.
    Lanham HT; Viriyakitja W; Vestal M; Welsby I; Kram B
    J Thromb Thrombolysis; 2024 Feb; 57(2):285-292. PubMed ID: 37932587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In factor Xa inhibitor-related acute ICH, andexanet vs. usual care improved hemostatic efficacy but increased thrombotic events.
    Hunter BR; Kirschner JM
    Ann Intern Med; 2024 Sep; 177(9):JC101. PubMed ID: 39222512
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Role of FEIBA in Reversing Novel Oral Anticoagulants in Intracerebral Hemorrhage.
    Dibu JR; Weimer JM; Ahrens C; Manno E; Frontera JA
    Neurocrit Care; 2016 Jun; 24(3):413-9. PubMed ID: 26545367
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.
    Sartori M; Cosmi B
    J Thromb Thrombolysis; 2018 Apr; 45(3):345-352. PubMed ID: 29372400
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes in Antiplatelet-Associated Intracerebral Hemorrhage in the TICH-2 Randomized Controlled Trial.
    Law ZK; Desborough M; Roberts I; Al-Shahi Salman R; England TJ; Werring DJ; Robinson T; Krishnan K; Dineen R; Laska AC; Peters N; Egea-Guerrero JJ; Karlinski M; Christensen H; Roffe C; Bereczki D; Ozturk S; Thanabalan J; Collins R; Beridze M; Bath PM; Sprigg N
    J Am Heart Assoc; 2021 Feb; 10(5):e019130. PubMed ID: 33586453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.